Department of Behavioural Sciences and Learning, Linköping University , Linköping , Sweden.
PeerJ. 2013 Jul 9;1:e98. doi: 10.7717/peerj.98. Print 2013.
Background. Depression and anxiety disorders are major world-wide problems. There are no or few epidemiological studies investigating the prevalence of depression, generalized anxiety disorder and anxiety disorders in general in the Swedish population. Methods. Data were obtained by means of a postal survey administered to 3001 randomly selected adults. After two reminders response rate was 44.3%. Measures of depression and general anxiety were the 9-item Patient Health Questionnaire Depression Scale (PHQ-9) and the 7-item Generalized Anxiety Disorder Scale (GAD-7). The PHQ-9 identified participants who had experienced clinically significant depression (PHQ-9 ≥ 10), and who had a diagnosis of major depression (defined by using a PHQ-9 scoring algorithm). Clinically significant anxiety was defined as having a GAD-7 score ≥ 8. To specifically measure generalized anxiety disorder, the Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV) was used with an established cut-off. Health-related quality of life was measured using the EuroQol (EQ-5D). Experiences of treatments for psychiatric disorders were also assessed. Results. Around 17.2% (95% CI: 15.1-19.4) of the participants were experiencing clinically significant depression (10.8%; 95% CI: 9.1-12.5) and clinically significant anxiety (14.7%; 95% CI: 12.7-16.6). Among participants with either clinically significant depression or anxiety, nearly 50% had comorbid disorders. The point prevalence of major depression was 5.2% (95% CI: 4.0-6.5), and 8.8% (95% CI: 7.3-10.4) had GAD. Among those with either of these disorders, 28.2% had comorbid depression and GAD. There were, generally, significant gender differences, with more women having a disorder compared to men. Among those with depression or anxiety, only between half and two thirds had any treatment experience. Comorbidity was associated with higher symptom severity and lower health-related quality of life. Conclusions. Epidemiological data from the Swedish community collected in this study provide point prevalence rates of depression, anxiety disorders and their comorbidity. These conditions were shown in this study to be undertreated and associated with lower quality of life, that need further efforts regarding preventive and treatment interventions.
抑郁和焦虑障碍是全球性的主要问题。目前,在瑞典人群中,针对抑郁、广泛性焦虑障碍和一般焦虑障碍的流行情况,进行的流行病学研究很少或几乎没有。方法:通过向 3001 名随机选择的成年人邮寄问卷调查的方式获取数据。在两次提醒后,回复率为 44.3%。抑郁和广泛性焦虑的评估工具是 9 项患者健康问卷抑郁量表(PHQ-9)和 7 项广泛性焦虑障碍量表(GAD-7)。PHQ-9 可识别出经历过临床显著抑郁(PHQ-9≥10)和患有重度抑郁症(通过 PHQ-9 评分算法定义)的患者。临床显著焦虑定义为 GAD-7 评分≥8。为了专门测量广泛性焦虑症,使用了经过验证的广泛性焦虑症问卷-IV(GAD-Q-IV)和既定的截断值。健康相关生活质量使用 EuroQol(EQ-5D)进行测量。还评估了治疗精神障碍的经历。结果:约 17.2%(95%CI:15.1-19.4)的参与者存在临床显著抑郁(10.8%;95%CI:9.1-12.5)和临床显著焦虑(14.7%;95%CI:12.7-16.6)。在患有临床显著抑郁或焦虑的参与者中,近 50%存在共病障碍。重度抑郁症的时点患病率为 5.2%(95%CI:4.0-6.5),8.8%(95%CI:7.3-10.4)患有广泛性焦虑症。在这些疾病中,28.2%的患者存在抑郁和广泛性焦虑共病。一般来说,存在显著的性别差异,女性患者的疾病发生率高于男性。在患有抑郁或焦虑的患者中,只有一半到三分之二的患者接受过任何治疗。共病与更高的症状严重程度和更低的健康相关生活质量相关。结论:本研究在瑞典社区收集的流行病学数据提供了抑郁、焦虑障碍及其共病的时点患病率。这些情况在本研究中显示出治疗不足,并与较低的生活质量相关,需要进一步努力开展预防和治疗干预。